Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Issue 8 (13th June 2012)

• Record Type: Journal Article
• Authors: Albert, Paul; Agusti, Alvar; Edwards, Lisa; Tal-Singer, Ruth; Yates, Julie; Bakke, Per; Celli, Bartolome R; Coxson, Harvey O; Crim, Courtney; Lomas, David A; MacNee, William; Miller, Bruce; Rennard, Stephen; Silverman, Edwin K; Vestbo, Jørgen; Wouters, Emiel; Calverley, Peter
• Is Part Of: Thorax. Volume 67:Issue 8(2012)
• Page Start: 701
• Page End: 708
• Publication Date: 2012-06-13
• Subjects: COPD exacerbations -- pulmonary rehabilitation -- COPD mechanisms -- emphysema -- COPD pharmacology -- cystic fibrosis -- cytokine biology -- exhaled airway markers -- innate immunity -- neutrophil biology -- viral infection -- asthma epidemiology -- COPD epidemiology -- assisted ventilation -- lung physiology -- lung volume reduction surgery -- respiratory muscles -- COPD pathology -- imaging/CT MRI etc -- pulmonary embolism -- alpha1 antitrypsin deficiency -- airway epithelium -- macrophage biology -- tobacco and the lung -- ambulatory oxygen therapy -- long-term oxygen therapy (LTOT) -- short burst oxygen therapy -- sleep apnoea -- chronic obstructive pulmonary disease -- bronchodilator reversibility -- phenotype; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2011-201458
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: Bronchodilator responsiveness is a potential phenotypic characteristic of chronic obstructive pulmonary disease (COPD). We studied whether change in lung function after a bronchodilator is abnormal in COPD, whether stable responder subgroups can be identified, and whether these subgroups experience different clinical outcomes. Methods: 1831 patients with COPD, 285 smoking (SC) and 228 non-smoking (NSC) controls from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Spirometric reversibility to 400 μg inhaled salbutamol was assessed on four occasions over 1 year. Results: Forced expiratory volume in 1 s (FEV1 ) increase after salbutamol was similar in SC (mean 0.14 litres (SD 0.15)) and COPD (0.12 litres (0.15)) and was significantly greater than NSC (0.08 litres (0.14)). Reversibility status varied with repeated testing in parallel with the day-to-day variation in pre-bronchodilator FEV1, which was similar in control subjects and patients with COPD. Absolute FEV1 change decreased by Global initiative for chronic Obstructive Lung Disease (GOLD) stage in patients with COPD (GOLD II, mean 0.16 litres (SD 0.17); III, 0.10 litres (0.13); IV, 0.05 litres (0.08) as did chances of being classified as reversible. CT-defined emphysema was weakly related to the absolute change in FEV1 post salbutamol. Consistently reversible patients (n=227) did not differ in mortality, hospitalisation or exacerbation experience from irreversible patients when allowing for differences in baseline FEV1 . Limitations: Reversibility only assessed with salbutamol and defined by FEV1 criteria. The COPD population was older than the control populations. Conclusions: Post-salbutamol FEV1 change is similar in patients with COPD and smoking controls but is influenced by baseline lung function and the presence of emphysema. Bronchodilator reversibility status varies temporally and does not distinguish clinically relevant outcomes, making it an unreliable phenotype. Clinical trial registration number: NCT00292552 (http://ClinicalTrials.gov ).